Bolt Biotherapeutics, Inc. (BOLT)

Over the past six months, Bolt Biotherapeutics' stock price has experienced a significant decline. As of March 26, 2026, the share price was $4.54, representing a 48.35% decrease from $8.79 on March 27, 2025. Key events impacting the stock include the Third Quarter 2025 Financial Results and business update on November 12, 2025, the Fourth Quarter and Full-Year 2025 Financial Results and business update on March 12, 2026, and a 20-for-1 stock split on June 9, 2025.

As a clinical-stage biopharmaceutical company, Bolt Biotherapeutics, Inc. does not experience traditional demand seasonality for its products and services. The demand for its pipeline candidates is driven by the progression of clinical trials, regulatory approvals, and the medical need for cancer treatments, rather than seasonal fluctuations.

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for cancer, operating in the Healthcare sector, specifically in Biotechnology & Medical Research, Drug Discovery, and Pharmaceutical Preparations. The company's Boltbody™ ISAC platform combines tumor-targeting antibodies with immune-stimulating linker-payloads to engage and activate myeloid cells, aiming to generate a robust anti-cancer response and immunological memory. The company's pipeline includes BDC-4182, a next-generation Boltbody™ ISAC targeting claudin 18.2, BDC-3042, an agonist antibody targeting Dectin-2, CEA ISAC, a Boltbody™ ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA), PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload and BDC-1001, a HER2 Boltbody™ ISAC that was in Phase 1/2 clinical trials. Bolt Biotherapeutics has collaboration agreements with companies such as Toray Industries, Genmab A/S, and Innovent Biologics, Inc., and a license agreement with Stanford University.

Bolt Biotherapeutics, Inc. is headquartered in Redwood City, California, United States, and operates primarily in the United States market.

Information explicitly detailing Bolt Biotherapeutics, Inc.'s brand reputation or specific events that have affected it in the past year is not readily available. The available information primarily focuses on scientific advancements, clinical trial progress, financial reporting, and corporate collaborations.

Bolt Biotherapeutics, Inc. is owned by a mix of institutional shareholders and individual insiders. As of March 26, 2026, the company had 23 institutional owners holding a total of 602,538 shares, including Sofinnova Investments, Inc., Pivotal bioVenture Partners Investment Advisor LLC, and Vivo Capital, LLC. Vivo Capital VIII LLC is the largest individual shareholder, owning 5.89 million shares representing 306.30% of the company.